Publicaciones en colaboración con investigadores/as de University College London (10)

2022

  1. Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire

    Annals of the rheumatic diseases, Vol. 81, Núm. 4, pp. 507-515

2020

  1. Racial differences in systemic sclerosis disease presentation: A European Scleroderma Trials and Research group study

    Rheumatology (United Kingdom), Vol. 59, Núm. 7, pp. 1684-1694

  2. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet Respiratory Medicine, Vol. 8, Núm. 10, pp. 963-974

2019

  1. Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis

    Arthritis and Rheumatology, Vol. 71, Núm. 9, pp. 1553-1570

  2. Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the european scleroderma trials and research (eustar) cohort

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 5, pp. 648-656

2018

  1. Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study

    Arthritis and Rheumatology, Vol. 70, Núm. 11, pp. 1829-1834

2017

  1. The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: Derivation and validation of a preliminarily revised EUSTAR activity index

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 1, pp. 270-276

  2. Update of EULAR recommendations for the treatment of systemic sclerosis

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 8, pp. 1327-1339

2012

  1. Inhibition of focal adhesion kinase prevents experimental lung fibrosis and myofibroblast formation

    Arthritis and Rheumatism, Vol. 64, Núm. 5, pp. 1653-1664

2009

  1. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis

    Annals of the Rheumatic Diseases, Vol. 68, Núm. 9, pp. 1433-1439